Thrombocytopenia in dengue infection raises concerns about bleeding risk. Of 256 patients with dengue infection who developed thrombocytopenia (platelet count, ! 3 20 ϫ 10 platelets/mL) without prior bleeding, 188 were given platelet transfusion. Subsequent bleeding, platelet increment, and platelet recovery were similar between patients given transfusion and patients not given transfusion. Prophylactic platelet transfusion was ineffective in preventing bleeding in adult patients with dengue infection.
in Singapore and Taiwan [2, 10] . We studied the impact of prophylactic platelet transfusion for severe thrombocytopenia in a large retrospective cohort of adults with acute dengue.
Methods. We studied all patients with acute dengue in 2004 who were admitted to the Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore [2] . Only patients who fulfilled the World Health Organization criteria for acute dengue (fever and у2 of the following symptoms: headache, eye pain, myalgia, arthralgia, leukopenia, rash, and bleeding) and who had results of laboratory diagnostic tests positive for dengue were included. All cases were classified as dengue fever, dengue hemorrhagic fever (all 4 criteria present: fever, thrombocytopenia [platelet count, ! platelets/mL], bleeding man-3 100 ϫ 10 ifestation, and plasma leakage), or DSS [5] . Patients with probable cases had acute dengue with positive results of serological analysis (Dengue Duo IgM & IgG Rapid Strip Test; Panbio), and those with confirmed cases had positive results of PCR. Medical chart review was performed to extract demographic characteristics, serial clinical and laboratory data, and treatment and outcome data.
Severe thrombocytopenia was defined as platelet count ! platelets/mL, on the basis of local clinical practice. 20 ϫ 10 were given prophylactic platelet transfusion were compared with those who were not given prophylactic platelet transfusion. Prophylactic platelet transfusion was given on the basis of a clinician's assessment. Outcome measures consisted of clinical bleeding after prophylactic platelet transfusion, platelet count increment the day after transfusion, time to platelet count 1 platelets/mL, length of hospitalization, and death. 3 50 ϫ 10 The x 2 test and Fisher's exact test were used to compare categorical variables, and Student's t test and the Mann-Whitney U test were used to compare continuous variables. All statistical analyses were performed using Stata, version 9.0 (Stata Corp), and tests were conducted with the significance level at 5%. Corresponding percentages, 5th and 95th percentiles, ORs, and 95% CIs are reported.
Results. In 2004, 1973 patients were admitted to our department at Tan Tock Seng Hospital who fulfilled the World Health Organization criteria for acute dengue and who had positive results of laboratory diagnostic tests. Of the cases, 54% were probable, and 46% were confirmed. There were 1855 patients with dengue fever and 118 patients with dengue hemorrhagic fever; 10 of the patients with dengue hemorrhagic fever had DSS. Seven patients required admission to the intensive care unit, and 1 patient died; all 8 of these patients had dengue hemorrhagic fever.
The median age was 32 years (5th-95th percentiles, 17-57 years), and 64% of patients were male. The median duration of illness at presentation was 5 days (5th-95th percentiles, 3-7 days), and the median length of hospital stay was 4 days (5th-95th percentiles, 2-7 days). At presentation, clinical bleeding occurred in 220 patients (85% had gum bleeding, 16% had epistaxis, 5% had menstrual bleeding, and 1% had gastrointestinal bleeding). The median platelet count nadir for patients with dengue fever was platelets/mL (5th-95th percen-3 51 ϫ 10 tiles, platelets/mL), compared with a median of 3 11-97 ϫ 10 platelets/mL (5th-95th percentiles, plate- 3 3 49 ϫ 10 9-90 ϫ 10 lets/mL) for patients with dengue hemorrhagic fever ( ). P 1 .05 Platelet transfusion was given to 249 patients (12.6%) during hospitalization (either prophylactic or therapeutic platelet transfusion); 61 of these patients received therapeutic transfusion.
Of the 1973 patients, 1666 had a platelet count nadir The baseline demographic and clinical variables on the day that the platelet count decreased to ! platelets/mL for 3 20 ϫ 10 the 256 patients who either were or were not given prophylactic platelet transfusion are shown in table 1. The median platelet count for both patients given transfusion and patients not given transfusion was platelets/mL (OR, 1.02; 95% CI, 0.94-3 15 ϫ 10 1.09;
). Patients given transfusion were more likely to P p .87 have fever (temperature, 138ЊC), compared with patients not given transfusion (33% vs. 18%; OR, 2.30; 95% CI, 1.15-4.59; ), and had significantly higher systolic blood pressure P p .02 (OR, 1.03; 95% CI, 1.01-1.06;
) and pulse pressure (OR, P p .01 1.02; 95% CI, 1.00-1.05;
). The median time from dis-P p .03 ease onset to hospital admission was 3 days (5th-95th percentiles, 2-6 days) for patients given transfusion, compared with 3 days (5th-95th percentiles, 1-6 days) for patients not given transfusion (
). The median time from disease onset to P p .38 platelet count ! platelets/mL and platelet transfusion 3 20 ϫ 10 was 5 days (5th-95th percentiles, 3-7 days) for patients given transfusion, compared with 4.5 days (5th-95th percentiles, 3-8 days) for patients not given transfusion (
). There were P p .94 no other significant demographic or clinical differences between the 2 groups.
The incidence of clinical bleeding was 6% among patients with platelet count 1 platelets/mL, 12% 
Among patients whose platelet count decreased to ! platelets/mL, prophylactic transfusion was given to 3 20 ϫ 10 188 patients at a median of 4 units of platelets (range, 1-12 units). Clinical bleeding subsequently occurred in 1 (0.5%) of 188 patients given prophylactic transfusion (severe gastrointestinal bleeding in a patient with known peptic ulcer disease who died due to disseminated intravascular coagulation and acute renal failure), compared with 2 (2.9%) of 68 patients not given transfusion ( ) (both instances of bleeding were P p .17 mild and did not require additional intervention). The median platelet increment on the day after platelet transfusion in patients given transfusion ( platelets/mL) was lower than 3 7 ϫ 10 the median platelet increment on the day after platelet count first decreased to ! platelets/mL in patients not given ). The median length of hospital stay was 6 days for P p .59 patients given transfusion, compared with 5 days for patients not given transfusion ( ). One patient died in the group P p .09 given transfusion, compared with none in group not given transfusion ( ). P p 1.00 Discussion. Prophylactic platelet transfusion is given because of the fear of severe bleeding in patients with acute dengue and thrombocytopenia. Experimental use of corticosteroid treatment and intravenous immunoglobulin treatment [3, 4] and the overuse of platelet transfusion [2, 10] have been reported. Platelet transfusion was given to 50.3% of hospitalized patients with dengue in Taiwan [10] and 12.6% in Singapore [2] . Only 7 patients in our study had severe bleeding-1 was in the group given transfusion, and the other 6 had a mean platelet count of platelets/mL (range, cytopenia in acute dengue infection does not correlate with bleeding risk. In pediatric DSS, thrombocytopenia did not predict severe bleeding in univariate analysis; the only 2 independent predictors of severe bleeding were shock and low hematocrit [8] . Another prospective pediatric study found that bleeding score did not correlate with platelet count [11] . Our large cohort of adults with acute dengue revealed that the incidence of clinical bleeding at hospital admission was independent of platelet count. The efficacy of prophylactic platelet transfusion and the threshold for transfusion is questionable. In a prospective study of acute myeloid leukemia, lowering the platelet threshold for prophylactic platelet transfusion from platelets/mL to 3 20 ϫ 10 platelets/mL did not increase the incidence of bleeding 3 10 ϫ 10 but significantly reduced the number of patients who received platelet transfusion [12] . In pediatric DSS, prophylactic transfusion of platelets and fresh frozen plasma did not reduce bleeding or expedite platelet recovery; instead, it caused fluid overload and prolonged hospitalization [9] . In addition, the improvement in platelet count was transient, lasting !5 h [9] . We have shown that prophylactic platelet transfusion did not improve relevant outcome measures, such as clinical bleeding, platelet increment, and platelet recovery.
Our study has several limitations. Its retrospective cohort design does not allow for increased recruitment, and the overall number of episodes of clinical bleeding was small (3 [1%] of 256 patients). The lack of randomization may have resulted in treatment bias, although both the transfusion and the nontransfusion groups had similar baseline features. Our cohort of patients with platelet count ! platelets/mL was limited 3 20 ϫ 10 to adult patients and included only 6 patients with dengue hemorrhagic fever, limiting the generalizability of our findings. Additional research on the role of prophylactic platelet transfusion in a randomized study with a larger cohort is needed.
Because our results revealed that there were no significant benefits of prophylactic platelet transfusion among adult patients with dengue, which are similar to results of other studies involving different cohorts, we no longer advocate prophylactic platelet transfusion given on the basis of platelet count for adults with acute uncomplicated dengue infection. This approach will save precious blood products and will reduce unnecessary patient exposure to transfusion risks.
